1887

Journal of General Virology header logo

Volume 87, Issue 9

A humanized murine monoclonal antibody protects mice either before or after challenge with virulent Venezuelan equine encephalomyelitis virus Free

Abstract

A humanized monoclonal antibody (mAb) has been developed and its potential to protect from or cure a Venezuelan equine encephalomyelitis virus (VEEV) infection was evaluated. The VEEV-neutralizing, protective murine mAb 3B4C-4 was humanized using combinatorial antibody libraries and phage-display technology. Humanized VEEV-binding Fabs were evaluated for virus-neutralizing capacity, then selected Fabs were converted to whole immunoglobulin (Ig) G1, and stable cell lines were generated. The humanized mAb Hy4-26C, designated Hy4 IgG, had virus-neutralizing capacity similar to that of 3B4C-4. Passive antibody protection studies with purified Hy4 IgG were performed in adult Swiss Webster mice. As little as 100 ng Hy4 IgG protected 90 % of mice challenged with 100 intraperitoneal (i.p.) mean morbidity (MD) doses of virulent VEEV (Trinidad donkey) 24 h after antibody transfer; also, 500 μg Hy4 IgG protected 80 % of mice inoculated with 100 intranasal MD doses of VEEV. Moreover, 10 μg passive Hy4 IgG protected 70 % of mice from a VEEV challenge dose as great as 10 i.p. MD. Hy4 IgG also protected mice from challenge with another epizootic VEEV variety, 1C (P676). Importantly, therapeutic administration of the humanized mAb to mice already infected with VEEV cured 90 % of mice treated with Hy4 IgG within 1 h of VEEV inoculation and 75 % of mice treated 24 h after virus infection.

  • Received:
  • Accepted:
  • Published Online:
© Microbiology Society
Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.81925-0
2006-09-01
2024-04-20
Loading full text...

Full text loading...

/deliver/fulltext/jgv/87/9/2467.html?itemId=/content/journal/jgv/10.1099/vir.0.81925-0&mimeType=html&fmt=ahah

References

  1. Barbas C. F., Burton D. R., Scott J. K. 2001 Phage Display: a Laboratory Manual Cold Spring Harbor, NY: Cold Spring Harbor Laboratory;
     [Google Scholar]
  2. Berge T. O., Banks I. S., Tiggert W. D. 1961; Attenuation of Venezuelan equine encephalomyelitis virus by in vitro cultivation in guinea-pig heart cells. Am J Hyg 73:209–218
     [Google Scholar]
  3. Bronze M. S., Huycke M. M., Machado L. J., Voskuhl G. W., Greenfield R. A. 2002; Viral agents as biological weapons and agents of bioterrorism. Am J Med Sci 323:316–325 [CrossRef]
     [Google Scholar]
  4. Burke D. S., Ramsburg H. H., Edelman R. 1977; Persistence in humans of antibody to subtypes of Venezuelan equine encephalomyelitis (VEE) virus after immunization with attenuated (TC-83) VEE virus vaccine. J Infect Dis 136:354–359 [CrossRef]
     [Google Scholar]
  5. Caron P. C., Dumont L., Scheinberg D. A. 1998; Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia. Clin Cancer Res 4:1421–1428
     [Google Scholar]
  6. Chalmers F. M., Curnow K. M. 2001; Scaling up the ligase chain reaction-based approach to gene synthesis. Biotechniques 30:249–252
     [Google Scholar]
  7. Ferguson J. A., Reeves W. C., Milby M. M., Hardy J. L. 1978; Study of homologous and heterologous antibody response in California horses vaccinated with attenuated Venezuelan equine encephalomyelitis vaccine (strain TC-83). Am J Vet Res 39:371–376
     [Google Scholar]
  8. Fillis C. A., Calisher C. H. 1979; Neutralizing antibody responses of humans and mice to vaccination with Venezuelan encephalitis (TC-83) virus. J Clin Microbiol 10:544–549
     [Google Scholar]
  9. Foote J., Winter G. 1992; Antibody framework residues affecting the conformation of the hypervariable loops. J Mol Biol 224:487–499 [CrossRef]
     [Google Scholar]
  10. Gordon M. S., Margolin K., Talpaz M., Sledge G. W. Jr, Holmgren E., Benjamin R., Stalter S., Shak S., Adelman D. 2001; Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19:843–850
     [Google Scholar]
  11. Groot H. 1972; The health and economic impact of Venezuelan equine encephalitis (VEE. In Venezuelan Encephalitis pp  7–16 Edited by PAH Organization Washington, DC:
     [Google Scholar]
  12. Hart M. K., Pratt W., Panelo F., Tammariello R., Dertzbaugh M. 1997; Venezuelan equine encephalitis virus vaccines induce mucosal IgA responses and protection from airborne infection in BALB/c, but not C3H/HeN mice. Vaccine 15:363–369 [CrossRef]
     [Google Scholar]
  13. Higo-Moriguchi K., Akahori Y., Iba Y., Kurosawa Y., Taniguchi K. 2004; Isolation of human monoclonal antibodies that neutralize human rotavirus. J Virol 78:3325–3332 [CrossRef]
     [Google Scholar]
  14. Hwang W. Y. K., Foote J. 2005; Immunogenicity of engineered antibodies. Methods 36:3–10 [CrossRef]
     [Google Scholar]
  15. Johnson K. M., Martin D. H. 1974; Venezuelan equine encephalitis. Adv Vet Sci Comp Med 18:79–116
     [Google Scholar]
  16. Johnson S., Oliver C., Prince G. A. & 13 other authors 1997; Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 176:1215–1224 [CrossRef]
     [Google Scholar]
  17. Johnstone R. E., Peters C. J. 1995; Alphaviruses. In Fields Virology , 3rd edn. pp  843–898 Edited by Fields B. N., Knipe D. M., Howley P. M. Philadelphia, PA: Lippincott–Raven;
     [Google Scholar]
  18. Kabat E. A., Wu T. T., Perry H. M., Gottesman K. S., Foeller C. 1991; Sequences of Proteins of Immunological Interest . , 5th edn. Edited by US Department of Health and Health Services Bethesda, MD:
     [Google Scholar]
  19. Kang A. S., Barbas C. F., Janda K. D., Benkovic S. J., Lerner R. A. 1991; Linkage of recognition and replication functions by assembling combinatorial antibody Fab libraries along phage surfaces. Proc Natl Acad Sci U S A 88:4363–4366 [CrossRef]
     [Google Scholar]
  20. Leonard J. P., Coleman M., Ketas J. C. & 14 other authors 2004; Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results. Clin Cancer Res 10:5297–5298 [CrossRef]
     [Google Scholar]
  21. Lord R. D. 1974; History and geographic distribution of Venezuelan equine encephalitis. Bull Pan Am Health Organ 8:100–110
     [Google Scholar]
  22. Maruyama T., Rodriguez L. L., Jahrling P. B., Sanchez A., Khan A. S., Nichol S. T., Peters C. J., Parren P. W. H. I., Burton D. R. 1999; Ebola virus can be effectively neutralized by antibody produced in natural human infection. J Virol 73:6024–6030
     [Google Scholar]
  23. Mathews J. H., Roehrig J. T. 1982; Determination of the protective epitopes on the glycoproteins of Venezuelan equine encephalomyelitis virus by passive transfer of monoclonal antibodies. J Immunol 129:2763–2767
     [Google Scholar]
  24. Mathews J. H., Roehrig J. T., Trent D. W. 1985; Role of complement and the Fc portion of immunoglobulin G in immunity to Venezuelan equine encephalomyelitis virus infection with glycoprotein-specific monoclonal antibodies. J Virol 55:594–600
     [Google Scholar]
  25. McCafferty J., Griffiths A. D., Winter G., Criswell D. J. 1990; Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348:552–554 [CrossRef]
     [Google Scholar]
  26. McKinney R. W. 1972; Inactivated and live VEE vaccines – a review. In Venezuelan Encephalitis pp  369–376 Edited by PAH Organization Washington DC:
     [Google Scholar]
  27. Men R., Yamashiro T., Goncalvez A. P., Wernly C., Schofield D. J., Emerson S. U., Purcell R. H., Lai C. J. 2004; Identification of chimpanzee Fab fragments by repertoire cloning and production of a full-length humanized immunoglobulin G1 antibody that is highly efficient for neutralization of dengue type 4 virus. J Virol 78:4665–4674 [CrossRef]
     [Google Scholar]
  28. Monath T. P. 1976; Togaviruses, bunyaviruses, and Colorado tick fever. In Handbook of Clinical Microbiology pp  597–603 Edited by Rose N. R., Friedman H. Washington, DC: American Society for Microbiology;
     [Google Scholar]
  29. Monath T. P., Trent D. W. 1981; Togaviral diseases of domestic animals. In Comparative Diagnosis of Viral Diseases pp  331–440 Edited by Kurstak E., Kurstak C. New York: Academic Press;
     [Google Scholar]
  30. Nishibori N., Horiuchi H., Furusawa S., Matsuda H. 2006; Humanization of chicken monoclonal antibody using phage-display system. Mol Immunol 43:634–642 [CrossRef]
     [Google Scholar]
  31. Obijeski J. F., Bishop D. H., Murphy F. A., Palmer E. L. 1976; Structural proteins of La Crosse virus. J Virol 19:985–997
     [Google Scholar]
  32. Paredes A., Alwell-Warda K., Weaver S. C., Chiu W., Watowich S. J. 2001; Venezuelan equine encephalomyelitis virus structure and its divergence from old world alphaviruses. J Virol 75:9532–9537 [CrossRef]
     [Google Scholar]
  33. Parren P. W. H. I., Burton D. R. 2001; The anti-viral activity of antibodies in vitro and in vivo. In Advances in Immunology pp  195–262 New York: Academic Press;
     [Google Scholar]
  34. Parren P. W. H. I., Gieisbert T. W., Maruyama T., Jahrling P. B., Burton D. R. 2002; Pre- and postexposure prophylaxis for Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. J Virol 76:6408–6412 [CrossRef]
     [Google Scholar]
  35. Phillpotts R. J., Jones L. D., Howard S. C. 2002; Monoclonal antibody protects mice against infection and disease when given either before or up to 24 h after airborne challenge with virulent Venezuelan equine encephalitis virus. Vaccine 20:1497–1504 [CrossRef]
     [Google Scholar]
  36. Phinney B. S., Blackburn K., Brown D. T. 2000; The surface conformation of Sindbis virus glycoproteins E1 and E2 at neutral and low pH, as determined by mass spectrometry-based mapping. J Virol 74:5667–5678 [CrossRef]
     [Google Scholar]
  37. Pittman P. R., Makuch R. S., Mangiafico J. A., Cannon T. L., Gibbs P. H., Peters C. J. 1996; Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine. Vaccine 14:337–343 [CrossRef]
     [Google Scholar]
  38. Rader C., Cheresh D. A., Barbas C. F. III 1998; A phage display approach for rapid antibody humanization: designed combinatorial V gene libraries. Proc Natl Acad Sci U S A 95:8910–8915 [CrossRef]
     [Google Scholar]
  39. Rader C., Ritter G., Nathan S. & 7 other authors 2000; The rabbit antibody repertoire as a novel source for the generation of therapeutic human antibodies. J Biol Chem 275:13668–13676 [CrossRef]
     [Google Scholar]
  40. Rivas F., Diaz L. A., Cardenas V. M. & 18 other authors 1997; Epidemic Venezuelan equine encephalitis in La Guajira. Colombia: 1995 J Infect Dis 175:828–832 [CrossRef]
     [Google Scholar]
  41. Roehrig J. T., Mathews J. H. 1985; The neutralization site on the E2 glycoprotein of Venezuelan equine encephalomyelitis (TC-83) virus is composed of multiple conformationally stable epitopes. Virology 142:347–356 [CrossRef]
     [Google Scholar]
  42. Roehrig J. T., Corser J. A., Schlesinger M. J. 1980; Isolation and characterization of hybrid cell lines producing monoclonal antibodies directed against the structural proteins of Sindbis virus. Virology 101:41–49 [CrossRef]
     [Google Scholar]
  43. Roehrig J. T., Day J. W., Kinney R. M. 1982; Antigenic analysis of the surface glycoproteins of a Venezuelan equine encephalomyelitis virus (TC-83) using monoclonal antibodies. Virology 118:269–278 [CrossRef]
     [Google Scholar]
  44. Roehrig J. T., Hunt A. R., Kinney R. M., Mathews J. H. 1988; In vitro mechanisms of monoclonal antibody neutralization of alphaviruses. Virology 165:66–73 [CrossRef]
     [Google Scholar]
  45. Santos A. D., Padlan E. A. 1998; Development of more efficacious antibodies for medical therapy and diagnosis. Prog Nucleic Acid Res Mol Biol 60:169–194
     [Google Scholar]
  46. Scott J. K., Smith G. P. 1990; Searching for peptide ligands with an epitope library. Science 249:386–390 [CrossRef]
     [Google Scholar]
  47. Sharman R. 1972; Equine diseases. In Venezuelan Encephalitis pp  221–223 Edited by PAH Organization Washington, DC:
     [Google Scholar]
  48. Sluiter W., Oomens L. W., Brand A., Van Furth R. 1984; Determination of blood volume in the mouse with 51chromium-labelled erythrocytes. J Immunol Methods 73:221–225 [CrossRef]
     [Google Scholar]
  49. Smith G. P. 1985; Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 228:1315–1317 [CrossRef]
     [Google Scholar]
  50. Steinberger P., Sutton J. K., Rader C., Elia M., Barbas C. F. III 2000; Generation and characterization of a recombinant human CCR5-specific antibody. A phage display approach for rabbit antibody humanization. J Biol Chem 275:36073–36078 [CrossRef]
     [Google Scholar]
  51. Sutton D. W., Havstad P. K., Kemp J. D. 1995; Rapid gene synthesis using ampligase thermostable DNA ligase. Epicentre Forum 2:1–2
     [Google Scholar]
  52. Tempest P. R., Bremmer P., Lambert M., Taylor G., Furze J. M., Carr F. J., Harris W. J. 1991; Reshaping a human monoclonal antibody to inhibit human respiratory syncytial virus infection in vivo. Biotechnology 9:266–276 [CrossRef]
     [Google Scholar]
  53. Tsui P., Tornetta M. A., Ames R. S., Bankosky B. C., Griego S., Silverman C., Porter T., Moore G., Sweet R. W. 1996; Isolation of neutralizing human RSV antibody from a dominant, non-neutralizing immune repertoire by epitope-blocked panning. J Immunol 157:772–780
     [Google Scholar]
  54. Tsurushita N., Hinton P. R., Kumar S. 2005; Design of humanized antibodies: from anti-Tac to Zenapax. Methods 36:69–83 [CrossRef]
     [Google Scholar]
  55. Walton T. E., Johnson K. M. 1972; Epizootiology of Venezuelan equine encephalomyelitis in the Americas. J Am Vet Med Assoc 161:1509–1515
     [Google Scholar]
  56. Woodle E. S., Xu D., Zivin R. A. & 8 other authors 1999; Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma (Ala-Ala) in the treatment of acute renal allograft rejection. Transplantation 68:608–616 [CrossRef]
     [Google Scholar]
  57. Zhang W., Mukhopadhyay S., Pletnev S. V., Baker T. S., Kuhn R. J., Rossman M. G. 2002; Placement of the structural proteins of Sindbis virus. J Virol 76:11645–11658 [CrossRef]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.81925-0
Loading
A humanized murine monoclonal antibody protects mice either before or after challenge with virulent Venezuelan equine encephalomyelitis virus
J. Gen. Virol. 87, 2467 (2006); https://doi.org/10.1099/vir.0.81925-0
/content/journal/jgv/10.1099/vir.0.81925-0
/content/journal/jgv/10.1099/vir.0.81925-0
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error